Mumbai, May 16 -- Aurobindo Pharma announced that CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva(R), a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The

authorisation permits manufacture at CuraTeQ's facility in Hyderabad and marketing of Bevqolva(R) in 100 mg/4mL and 400 mg/16 mL vial presentations.

Published by HT Digital Content Services with permission from Capital Market....